Disc Medicine (NASDAQ:IRON) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Disc Medicine (NASDAQ:IRON) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

IRON has been the subject of several other reports. Morgan Stanley boosted their target price on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Finally, Wedbush reaffirmed an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.44.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $77.00 on Friday. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The firm has a market capitalization of $2.94 billion, a P/E ratio of -11.70 and a beta of 0.97. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The company’s fifty day moving average price is $72.74 and its 200 day moving average price is $69.69.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. As a group, sell-side analysts predict that Disc Medicine will post -6.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,758,677.56. The trade was a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 34,000 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at $15,871,953.44. This trade represents a 13.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 105,712 shares of company stock worth $7,597,536. 3.76% of the stock is owned by company insiders.

Institutional Trading of Disc Medicine

Hedge funds have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $33,000. KBC Group NV purchased a new stake in shares of Disc Medicine during the fourth quarter worth approximately $80,000. Persistent Asset Partners Ltd acquired a new stake in shares of Disc Medicine during the fourth quarter worth $141,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Disc Medicine by 36.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Disc Medicine by 15,137.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock valued at $161,000 after buying an additional 2,422 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.